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Loss-of-function mutations of GNA11, which encodes G-protein subunit a11 (Ga11), a
signaling partner for the calcium-sensing receptor (CaSR), result in familial hypocalciuric
hypercalcemia type 2 (FHH2). FHH2 is characterized by hypercalcemia, inappropriately
normal or raised parathyroid hormone (PTH) concentrations, and normal or low urinary
calcium excretion. A mouse model for FHH2 that would facilitate investigations of the in vivo
role of Ga11 and the evaluation of calcimimetic drugs, which are CaSR allosteric activators,
is not available. We therefore screened DNA from > 10,000 mice treated with the chemical
mutagen N-ethyl-N-nitrosourea (ENU) for GNA11 mutations and identified a Ga11 variant,
Asp195Gly (D195G), which downregulated CaSR-mediated intracellular calcium signaling
in vitro, consistent with it being a loss-of-function mutation. Treatment with the calcimimetic
cinacalcet rectified these signaling responses. In vivo studies showed mutant heterozygous
(Gna11+/195G) and homozygous (Gna11195G/195G) mice to be hypercalcemic with normal or
increased plasma PTH concentrations and normal urinary calcium excretion. Cinacalcet
(30mg/kg orally) significantly reduced plasma albumin–adjusted calcium and PTH
concentrations in Gna11+/195G and Gna11195G/195G mice. Thus, our studies have
established a mouse model with a germline loss-of-function Ga11 mutation that is
representative for FHH2 in humans and demonstrated that cinacalcet can correct the
associated abnormalities of plasma calcium and PTH.
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Introduction
Familial hypocalciuric hypercalcemia (FHH) is an autosomal dominant disorder of  extracellular calcium 
(Ca2+o) homeostasis characterized by lifelong elevations in serum calcium concentrations in association 
with normal or mildly elevated serum parathyroid hormone (PTH) concentrations and normal or low 
fractional excretion of  calcium (1–4). FHH is caused by a reduction in the sensitivity of  the Ca2+o-sensing 
receptor (CaSR) signaling pathway to alterations in the prevailing Ca2+o concentration ([Ca
2+]o) (1–4). The 
CaSR is a widely expressed family C GPCR that regulates PTH secretion and urinary calcium excretion 
by transducing elevations in [Ca2+]o into multiple intracellular signaling cascades in the parathyroid glands 
and kidneys, respectively (5, 6). In the parathyroid glands, the CaSR has been shown to couple to the Gq/11 
protein family (7), which activates phospholipase C (PLC), thereby increasing intracellular calcium (Ca2+i) 
and MAPK signaling responses (8, 9), which in turn leads to decreased parathyroid PTH secretion.
FHH is a genetically heterogeneous disorder with 3 recognized forms referred to as FHH types 
1–3 (FHH1-3) (1). FHH1 (OMIM 145980) is caused by heterozygous loss-of-function mutations of  the 
CaSR, which is encoded by the CASR gene on chromosome 3q21.1 (1). FHH2 (OMIM 145981) is due to 
heterozygous loss-of-function mutations of  G-protein subunit α11 (Gα11), which is encoded by the GNA11 
gene on chromosome 19p13.3, and to date, 3 FHH2-associated mutations have been reported, compris-
ing 2 missense mutations, Thr54Met and Leu135Gln, and an in-frame isoleucine deletion at codon 200 
(Ile200del) (3, 10). FHH3 (OMIM 600740) is caused by heterozygous loss-of-function mutations of  the 
adaptor protein-2 σ subunit (AP2σ), encoded by the AP2S1 gene on chromosome 19q13.3, which is involved 
in the clathrin-mediated endocytosis of  cell-surface proteins such as the CaSR (4, 11).
Loss-of-function mutations of GNA11, which encodes G-protein subunit α11 (Gα11), a signaling partner 
for the calcium-sensing receptor (CaSR), result in familial hypocalciuric hypercalcemia type 2 (FHH2). 
FHH2 is characterized by hypercalcemia, inappropriately normal or raised parathyroid hormone 
(PTH) concentrations, and normal or low urinary calcium excretion. A mouse model for FHH2 that 
would facilitate investigations of the in vivo role of Gα11 and the evaluation of calcimimetic drugs, 
which are CaSR allosteric activators, is not available. We therefore screened DNA from > 10,000 
mice treated with the chemical mutagen N-ethyl-N-nitrosourea (ENU) for GNA11 mutations and 
identified a Gα11 variant, Asp195Gly (D195G), which downregulated CaSR-mediated intracellular 
calcium signaling in vitro, consistent with it being a loss-of-function mutation. Treatment with 
the calcimimetic cinacalcet rectified these signaling responses. In vivo studies showed mutant 
heterozygous (Gna11+/195G) and homozygous (Gna11195G/195G) mice to be hypercalcemic with normal or 
increased plasma PTH concentrations and normal urinary calcium excretion. Cinacalcet (30mg/kg 
orally) significantly reduced plasma albumin–adjusted calcium and PTH concentrations in Gna11+/195G 
and Gna11195G/195G mice. Thus, our studies have established a mouse model with a germline loss-of-
function Gα11 mutation that is representative for FHH2 in humans and demonstrated that cinacalcet 
can correct the associated abnormalities of plasma calcium and PTH.
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A mouse model for FHH1 has previously been generated by targeted germline disruption of the Casr gene, 
and heterozygous (Casr+/–) mice were shown to have a phenotype resembling that of FHH1 patients with ele-
vated serum concentrations of calcium and PTH, and low urinary calcium excretion (12). In addition, homo-
zygous (Casr–/–) mice had features of neonatal severe hyperparathyroidism (NSHPT), which is caused by bial-
lelic inactivating CaSR mutations (1), and exhibited growth retardation and died within the first 30 days of life 
(12). An in vivo model is not available for FHH2, although mice with parathyroid-specific combined ablations 
of both the Gna11 and Gnaq (encoding Gαq) genes have previously been reported to develop marked hypercal-
cemia and hyperparathyroidism (7). We therefore sought to establish a mouse model for FHH2 to define the 
in vivo role of Gα11 in Ca
2+
o homeostasis and to undertake a more detailed characterization of the phenotype 
of this disorder, as limited information is available from the few FHH2 patients reported, to date (3, 10). In 
addition, a mouse model for FHH2 would facilitate evaluation of therapeutic drugs such as CaSR allosteric 
activators, also known as calcimimetics (13). To establish a mouse model for FHH2, due to a germline loss-
of-function GNA11 point mutation (3, 10), we screened a DNA archive of > 10,000 samples from male mice 
that had mutations induced by treating them with N-ethyl-N-nitrosourea (ENU), a chemical mutagen. ENU is 
an alkylating agent that introduces point mutations via transfer of an alkyl group from ENU to a DNA base, 
thus leading to mispairing and bp substitution during subsequent DNA replication (14, 15). ENU mutagenesis 
programs utilize two complementary approaches that are phenotype-driven and genotype-driven screens. In 
phenotype-driven screens, offspring of mutagenized mice are assessed for abnormalities in a hypothesis-gen-
erating strategy, which may elucidate new genes, pathways, and mechanisms for disease phenotypes (14, 15). 
Genotype-driven screens in which mutations in the gene of interest are sought are hypothesis driven and are 
feasible by available parallel archives of tissue-DNA and sperm samples from mutagenized male mice (14, 
15). The archived tissue-DNA samples from the mutagenized male mice are used to search for the mutations 
in the gene of interest, and once these mutations are found, a sperm sample from the male mouse with the 
mutation is used for in vitro fertilization (IVF) of normal female mice to establish progeny with the mutation 
(14, 15). The probability of finding 3 or more variant alleles in an archive of tissue-DNA samples from > 5,000 
ENU-mutagenized mice is > 90% (14). We sought for ENU-induced Gna11 variants in tissue-DNA samples 
from > 10,000 male mice treated with ENU, with the aim of establishing a mouse model for FHH2.
Results
Identification and analysis of  5 Gna11 variants in ENU-mutagenized mice. An analysis using melting curve analysis 
(16) of tissue-DNA samples from > 10,000 ENU-mutagenized male mice of the 7 exons and 12 intron-exon 
boundaries of the Gna11 gene revealed the presence of 5 Gna11 variants, comprising c.379C>T, c.395T>A, 
c.440G>A, c.584A>G, and c.806T>C (numbering starts from ATG; Supplemental Table 1; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.96540DS1; numbering in Sup-
plemental Table 1 starts from 5′UTR.). These 5 Gna11 variants predicted the occurrence of 4 missense vari-
ants (Ile132Asn, Arg147His, Asp195Gly, and Val269Ala) and 1 nonsense variant (Gln127Stop) (Figure 1A 
and Supplemental Figure 1). Bioinformatic analysis predicted all the Gα11 variants to be damaging and likely 
disease-causing (Supplemental Table 1). FHH2 has been reported to be caused by either an in-frame deletion 
or missense substitutions affecting Gα11 (3, 10), and we therefore further characterized only the 4 missense 
Gα11 variants identified in ENU-mutagenized mice. All of these 4 missense variants affected evolutionary-con-
served residues (Figure 1B, Supplemental Table 1, and Supplemental Figure 1), and 2 variants (Asp195Gly and 
Val269Ala) were located in the Gα11 GTPase domain, which mediates GPCR binding, guanosine triphosphate 
(GTP) hydrolysis, and effector coupling. The other 2 variants (Ile132Asn and Arg147His) were located in the 
Gα11 helical domain, which stabilizes guanine nucleotide binding (Figure 1A and Supplemental Figure 1) (17). 
Three-dimensional (3-D) modeling using the reported crystal structure of the related Gαq protein (18) predicted 
the Asp195Gly variant to disrupt polar contacts within the Gα11 GTPase domain (Figure 1, C and D), whereas 
the other missense variants were not predicted to alter intramolecular interactions within the Gα11 protein 
(Supplemental Figure 1). We therefore selected the Asp195Gly (D195G) variant for functional characterization 
for the following 4 reasons. First, this variant is located within the switch regions of the Gα11 GTPase domain 
(Figure 1, B and C), which are critical for mediating Gα-subunit conformational changes upon GTP binding 
and also for coupling to downstream effector proteins such as PLC (19, 20). Second, the Asp195Gly variant is 
situated within a 13 amino acid region (residues 193–205), which links switches I and II (Figure 1, B and C) 
and is the location of a reported FHH2-causing Gα11 mutation (Ile200del) (3). Third, this 13–amino acid linker 
region also contains the tetrapeptide β2-β3 loop (residues 196–199), which mediates G-protein–GPCR inter-
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actions (21) (Figure 1C), and our reported mutagenesis studies have shown that disruption of the Gα11 β2-β3 
loop impairs signaling in CaSR-expressing cells (3). Fourth, 3-D modeling of the Asp195Gly Gα11 variant 
predicted that substitution of the WT Asp195 residue with the variant Gly195 residue would lead to a loss of  
a polar contact within the Gα11 β2-β3 loop, which would likely disrupt this tetrapeptide loop (Figure 1D) and 
thereby impair GPCR binding and Gα11 activation (3, 19, 20). These combined observations indicated that the 
Asp195Gly variant was highly likely to be a pathogenic mutation.
In vitro functional characterization of  the Asp195Gly Gα11 mutation. To investigate the effects of  these predict-
ed Gα11 structural changes due to the Asp195Gly mutation on CaSR-mediated signaling, human embryon-
ic kidney 293 (HEK293) cells stably expressing the CaSR (HEK-CaSR) were transiently transfected with 
pBI-CMV2-GNA11-GFP constructs expressing either the WT (Asp195) or variant (Gly195) Gα11 proteins, as 
reported (3). This bidirectional pBI-CMV2 vector allows for coexpression of  Gα11 and GFP at equivalent lev-
els (3). Expression of  the CaSR, Gα11, and GFP was confirmed by fluorescence microscopy and/or Western 
blot analyses (Figure 2, A and B). The expression of  Gα11 was shown to be similar in cells transiently transfect-
ed with WT or mutant proteins and to be greater than that observed in untransfected cells (Figure 2B). More-
over, the expression of  mutant Gα11 in cells that endogenously express WT Gα11 (Figure 2B) corresponded 
to the heterozygous situation reported in FHH2 patients (3, 10). The Ca2+i responses to alterations in [Ca
2+]o 
of  cells expressing the different GNA11 vectors were assessed using a multiwell assay that utilized the Fluo-4 
Ca2+–binding dye, as reported (22). The Ca2+i responses were shown to increase in a dose-dependent manner 
following stimulation with increasing [Ca2+]o (Figure 2C). However, responses in mutant Gly195–expressing 
Figure 1. Structural characterization of the Asp195Gly Gα11 mutation. (A) Genomic organization of Gna11 showing the location of reported human familial 
hypocalciuric hypercalcemia type 2 (FHH2) mutations (black) (3, 10) and Gna11 variants identified in N-ethyl-N-nitrosourea– mutagenized (ENU-mutagen-
ized) mice (red). The G-protein subunit α11 (Gα11) GTPase domain (encoded by exon 1, 5′ portion of exon 2, 3′portion of exon 4 and exons 5–7) is connected to 
the helical domain (encoded by the 3′portion of exon 2, exon 3, and 5′portion of exon 4) by the linker 1 (L1) and 2 (L2) peptides. The GTPase domain contains 3 
flexible regions, termed switch regions I–III (SwI–SwIII). The Asp195Gly mutation is located within the GTPase domain and between the switch I and II regions. 
(B) Multiple protein sequence alignment of Gα11 residues comprising a 13–amino acid region that links the β2 strand of the switch I region with the β3 strand 
of the switch II region. Conserved residues are shown in gray. The WT (Asp, D) and mutant (m) (Gly, G) residues are shown in red. (C) Homology model of the 
GDP-bound Gα11 protein. The Gα helical (blue) and GTPase (green) domains and bound GDP nucleotide (black) are shown. Switch regions I–III are shown in 
orange. Previously reported residues mutated in FHH2 patients (3, 10) are shown in yellow. The mutated Asp195 residue (red) is located in a 13–amino acid 
region (gray) and adjacent to the β2-β3 loop. (D) Close-up view the β2-β3 hairpin loop region of WT and mutant Gα11 proteins showing the structural effects of 
the Asp195Gly mutant on hydrogen bonds (broken lines) within the hairpin loop. The Asp195Gly Gα11 mutant is predicted to result in a loss of a polar contact 
(hydrogen bond) between the Asp195 side chain and the backbone of the Glu197 (E197) residue. The one-letter amino acid codes indicate the following: D, 
aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; I, isoleucine; L, leucine; M, methionine; N, asparagine; Q, glutamine; and T, threonine.
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cells were significantly decreased compared with WT-expressing cells (Figure 2C). Thus, the mutant Gly195–
expressing cells showed a rightward shift in the concentration-response curve (Figure 2C), with a significantly 
increased mean half-maximal response (EC50) of  3.39 mM (95% CI, 3.26–3.53 mM) compared with 2.70 mM 
(95% CI, 2.53–2.88 mM) for WT-expressing (Asp195) cells (P < 0.0001) (Figure 2, C and D). These results 
demonstrated that the Gα11 Asp195Gly mutation is a loss-of-function mutation, similar to mutations that lead 
to FHH2 (3, 10). We next investigated the ability of  the CaSR allosteric activator, cinacalcet, to rectify this loss 
of  function associated with the Asp195Gly Gα11 mutation. Cinacalcet was added to Gly195 mutant cells at a 
10 nM concentration, as this dose has previously been reported to normalize the altered signaling responses 
associated with FHH2-causing Gα11 mutations in vitro (23). An assessment of  Ca
2+
i responses showed 10 
nM cinacalcet to induce a leftward shift of  the concentration-response curve of  cells expressing the Gly195 
mutant Gα11 protein (Figure 2C) and decrease their mean EC50 value to 2.70 mM (95% CI, 2.60–2.80 mM), 
a value that was indistinguishable from the EC50
 
of  untreated WT cells (Figure 2, C and D). Thus, cinacalcet 
normalized the signaling responses of  Gly195 mutant cells.
Figure 2. Ca2+i responses of the Gly195 Gα11 mutant and in vitro effect of cinacalcet treatment. (A) Fluorescence microscopy of untransfected (UT) HEK293 
cells stably expressing calcium-sensing receptor (CaSR) (HEK-CaSR) and of HEK-CaSR cells transiently transfected with WT (Asp195) or mutant (m) Gly195 
pBI-CMV2-GNA11-GFP constructs. GFP expression in these cells indicates successful transfection and expression by these constructs. Scale bar: 10 μm. 
(B) Western blot analysis of lysates from HEK-CaSR cells used for intracellular calcium (Ca2+i) experiments. Transient transfection with WT or mutant 
Gly195 G-protein subunit α11 (Gα11) expression constructs resulted in overexpression of Gα11 and GFP, whereas UT cells showed only endogenous Gα11 protein 
expression. All cells expressed the CaSR. The calnexin and GAPDH proteins were used as loading controls. (C) Ca2+i responses to changes in [Ca2+]o of HEK-
CaSR cells expressing WT or Gly195 Gα11 mutant proteins. The Ca
2+
i responses are expressed as a percentage of the maximum normalized responses and 
shown as the mean ± SEM of 8 independent transfections. The Gly195 Gα11 mutant led to a rightward shift in the concentration-response curve (red line) 
compared with cells expressing WT Gα11 (black line). The addition of 10 nM cinacalcet (Cin) normalized the shift of the mutant concentration-response 
curve (blue line). (D) Histogram showing the mean half-maximal concentration (EC50) with 95% CI of WT cells (black), Gly195 mutant cells (red), and Gly195 
mutant cells treated with 10 nM cinacalcet (blue). Statistical analysis was performed using the F-test. ****P < 0.0001 compared with WT.
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In vivo functional analysis in mice harboring the germline Gna11 Asp195Gly mutation. To investigate the 
in vivo effects of  the Asp195Gly Gα11 mutation on Ca
2+
o homeostasis, ENU mutagenesis–derived mice 
harboring this mutation were established on the C3H inbred genetic background (24). DNA sequence 
analysis confirmed the mutant mice to harbor a germline A-to-G transition at c.584A>G at codon 
195 of  the Gα11 protein resulting in an Asp (D) to Gly (G) missense substitution (Figure 3, A and 
B). This mutation led to a gain of  a HaeIII restriction endonuclease site (Figure 3C), which was used 
to confirm the presence of  the mutation (Figure 3D) and to genotype the subsequent generations of  
mice. Heterozygous-affected (Gna11+/195G) mice were healthy and fertile, and an analysis of  offspring 
bred from crosses of  Gna11+/195G mice yielded homozygous-affected (Gna11195G/195G) mice and significant 
deviations from the Mendelian inheritance expected ratio of  1:2:1 for the WT (Gna11+/+), Gna11+/195G, 
and Gna11195G/195G genotypes were not observed among the weaned mice, thereby indicating that the 
homozygous Gna11195G/195G mice were viable and did not have embryonic or neonatal lethality (Table 1). 
Moreover, Gna11195G/195G mice had a normal body weight compared with WT (Gna11+/+) and Gna11+/195G 
littermates (Table 2). Thus, Gna11195G/195G mice did not have evidence of  growth retardation or neonatal 
lethality to suggest an NSHPT phenotype. However, plasma biochemical analysis revealed Gna11+/195G 
and Gna11195G/195G mice to be significantly hypercalcemic compared with Gna11+/+ mice (Figure 4A). 
Moreover, Gna11195G/195G mice had significantly reduced plasma phosphate concentrations and raised 
Figure 3. DNA sequence and restriction endonuclease analysis of the Asp195Gly Gα11 mutation. (A) DNA sequence analysis showing an A-to-G transition at 
c.584 (red arrow) within exon 3 of Gna11 (numbering begins from ATG). The DNA sequence chromatograms show that WT (Gna11+/+) mice are homozygous A/A, 
the heterozygous mutant Gna11+/195G mice are A/G, and the homozygous mutant Gna11195G/195G mice are G/G. (B) This A-to-G transition was predicted to lead to a 
missense substitution of Asp, encoded by GAC, to Gly, encoded by GGC, at codon 195 and resulted in the gain of a HaeIII restriction endonuclease (RE) site (GG/
CC). (C) Restriction maps showing that HaeIII digest would result in 2 products of 108 bp and 225 bp for the WT, and 3 products of 108 bp, 146 bp, and 79 bp for 
the mutant (m). (D) RE digest of Gna11 exon 3 PCR products demonstrating that WT (Gna11+/+) mice are homozygous for the WT alleles, mutant Gna11+/195G 
mice are heterozygous and have WT and m alleles, and mutant Gna11195G/195G mice are homozygous for m alleles. M, male; F, female; S, size marker.
Table 1. Proportion of offspring bred from crosses of Gna11+/195G × Gna11+/195G mice
Genotype Expected number of offspring (n = 358 born) Observed number of offspring (n = 234 weaned)
+/+ 89 (25%) 56 (24%)
+/195G 180 (50%) 127 (54%)
195G /195G 89 (25%) 51 (22%)
The Mendelian inheritance expected ratio from heterozygous crosses is 1:2:1, and χ2 analysis shows no significant differences in the expected vs. observed 
ratios of offspring genotypes at weaning (i.e., 19–21 days of age) (x2 = 1.0, degrees of freedom = 2).
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plasma PTH concentrations when compared with Gna11+/+ mice, whereas Gna11+/195G mice had plasma 
phosphate and PTH concentrations that were similar to those of  Gna11+/+ mice (Figure 4, B and C). 
Furthermore, the fractional excretion of  calcium was not altered in Gna11+/195G or Gna11195G/195G mice 
compared with Gna11+/+ mice (Figure 4D and Table 3). However, there were sex differences in these 
calcitropic phenotypes, as follows. Female Gna11195G/195G mice were significantly more hypercalcemic 
than male Gna11195G/195G mice and female Gna11+/195G mice (Table 2 and Supplemental Figure 2). In addi-
tion, female Gna11195G/195G mice, but not the Gna11 mutant males, had significant hypophosphatemia, 
with a significant reduction in the tubular maximum reabsorption of  phosphate (Table 3) and a raised 
alkaline phosphatase activity compared with female Gna11+/+ mice (Table 2 and Supplemental Figure 
2). Significant differences were not observed in plasma electrolytes, urea and creatinine concentrations, 
or 1,25-dihydroxyvitamin D or fibroblast growth factor-23 (FGF-23) concentrations in male or female 
Gna11+/195G and Gna11195G/195G mice, when compared with respective Gna11+/+ mice (Table 2). The frac-
tional excretions of  sodium and potassium were also not different between male and female mutant 
mice and respective Gna11+/+ mice (Table 3). Finally, whole body dual-energy X-ray absorptiometry 
(DXA) did not reveal significant differences in the bone mineral content or bone mineral density (BMD) 
between male and female mutant mice and respective Gna11+/+ mice (Table 4).
To determine whether the hypercalcemia of  Gna11+/195G and Gna11195G/195G mice may be improved by 
in vivo calcimimetic treatment, we administered cinacalcet to WT and mutant mice. A pilot dose-rang-
ing study in WT mice showed that a single oral gavage 30 mg/kg dose of  cinacalcet significantly low-
ered plasma PTH concentrations, when compared with vehicle-treated mice (Supplemental Figure 3). 
This dose (30mg/kg) of  cinacalcet was therefore administered by oral gavage to Gna11+/+, Gna11+/195G, 
and Gna11195G/195G mice, and plasma samples were then taken at 0, 1, 2, 4, 6, and 24 hours after dose for 
the measurement of  PTH, calcium, phosphate, urea, creatinine, and albumin concentrations. Admin-
istration of  cinacalcet significantly decreased plasma PTH concentrations in Gna11+/+, Gna11+/195G, and 
Gna11195G/195G mice by ≥ 60% at 1 hour after dose, with values returning to baseline by 4–6 hours after 
dose (Figure 5, A–C), and it significantly reduced plasma albumin–adjusted calcium concentrations in 
Gna11+/+, Gna11+/195G, and Gna11195G/195G mice between 2–6 hours after dose, with values returning to 
Table 2. Age, weight, and plasma biochemical profile of Gna11+/+, Gna11+/195G, and Gna11195G/195G mice
Parameter Male Female
Gna11+/+ Gna11+/195G Gna11195G/195G Gna11+/+ Gna11+/195G Gna11195G/195G
Age (weeks) 13.9 ± 0.1 (n = 12) 14.0 ± 0.1 (n = 13) 13.9 ± 0.1 (n = 14) 13.8 ± 0.1 (n = 10) 13.8 ± 0.1 (n = 15) 13.6 ± 0.1 (n = 13)
Weight (g) 31.7 ± 0.7 (n = 12) 31.4 ± 1.1 (n = 13) 32.3 ± 0.9 (n = 14) 27.5 ± 0.8 (n = 13) 30.2 ± 0.9 (n = 15) 30.2 ± 0.6 (n = 13)
Sodium (mmol/l) 149 ± 0.7 (n = 12) 151 ± 0.5 (n = 13) 150 ± 0.6 (n = 13) 149 ± 0.6 (n = 10) 148 ± 0.7 (n = 15) 147 ± 0.6 (n = 13)
Potassium (mmol/l) 5.4 ± 0.1 (n = 12) 5.2 ± 0.1 (n = 13) 5.3 ± 0.1 (n = 13) 5.0 ± 0.1 (n = 10) 4.9 ± 0.1 (n = 15) 4.9 ± 0.2 (n = 13)
Urea (mmol/l) 10.7 ± 0.6 (n = 12) 9.8 ± 0.3 (n = 13) 10.1 ± 0.4 (n = 13) 8.6 ± 0.6 (n = 10) 8.8 ± 0.2 (n = 15) 9.0 ± 0.3 (n = 12)
Creatinine (μmol/l) 11.6 ± 0.6 (n = 12) 10.8 ± 0.7 (n = 13) 12.0 ± 0.7 (n = 13) 12.7 ± 0.4 (n = 10) 12.8 ± 0.4 (n = 15) 12.4 ± 0.4 (n = 13)
Calcium (mmol/l) 2.36 ± 0.02 (n = 12) 2.40 ± 0.02 (n = 12) 2.48 ± 0.02 (n = 13)D 2.40+0.03 (n = 10) 2.46 ± 0.01 (n = 15) 2.59 ± 0.02 (n = 13)D,E
Adj-calcium 
(mmol/l)A
2.36 ± 0.02 (n = 12) 2.41 ± 0.02 (n = 12) 2.48 ± 0.02 (n = 13)D 2.39 ± 0.02 (n = 10) 2.45 ± 0.01 (n = 15) 2.58 ± 0.02 (n = 13)D,E
Albumin (g/l) 25.2 ± 0.3 (n = 12) 24.8 ± 0.3 (n = 12) 25.0 ± 0.2 (n = 13) 26.2 ± 0.4 (n = 10) 26.5 ± 0.4 (n = 15) 26.9 ± 0.4 (n = 13)
Magnesium 
(mmol/l)
0.80 ± 0.02 (n = 12) 0.76 ± 0.02 (n = 13) 0.76 ± 0.02 (n = 13) 0.81 ± 0.02 (n = 10) 0.83 ± 0.02 (n = 15) 0.85 ± 0.02 (n = 13)
Phosphate (mmol/l) 1.67 ± 0.11 (n = 12) 1.65 ± 0.08 (n = 13) 1.51 ± 0.08 (n = 13) 2.04 ± 0.12 (n = 10) 1.73 ± 0.05 (n = 15) 1.66 ± 0.11 (n = 13)B
ALP (U/l) 93.2 ± 3.3 (n = 12) 90.8 ± 4.9 (n = 13) 98.5 ± 3.2 (n = 13) 120 ± 4.5 (n = 10) 132 ± 3.5 (n = 15) 142 ± 6.5 (n = 13)B
PTH (ng/l) 417 ± 37 (n = 8) 562 ± 54 (n = 12) 813 ± 63 (n = 13)D 290 ± 34 (n = 10) 405 ± 43 (n = 12) 535 ± 36 (n = 9)C
1,25D (pmol/l) 74.5 ± 11 (n = 12) 64.7 ± 10 (n = 10) 90.7 ± 19 (n = 12) 72.8 ± 9 (n = 10) 76.8 ± 6 (n = 14) 86.3 ± 7 (n = 13)
FGF-23 (ng/l) 149 ± 7 (n = 12) 170 ± 5 (n = 11) 173 ± 8 (n = 12) 150 ± 4 (n = 10) 146 ± 7 (n = 14) 160 ± 8 (n = 13)
APlasma calcium concentrations were adjusted according to the mean plasma albumin concentration of respective male and female WT mice. Adj-calcium, 
albumin-adjusted calcium; ALP, alkaline phosphatase activity; PTH, parathyroid hormone; 1,25D, 1,25 dihydroxyvitamin D; FGF-23, fibroblast growth 
factor-23. All values are expressed as mean  ±  SEM. A Kruskal-Wallis test followed by Dunn’s test for nonparametric pairwise multiple comparisons were 
used to compare mutant mice with WT mice, and a Mann-Whitney U test was used to compare respective male and female mice. BP < 0.05, CP < 0.01, DP < 
0.001 compared with respective Gna11+/+ mice . EP < 0.001 compared with respective male mice.
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baseline by 24 hours after dose (Figure 5, D–F). Cinacalcet treatment also resulted in a transient rise in 
plasma phosphate concentrations in Gna11+/+, Gna11+/195G, and Gna11195G/195G mice (Figure 5, G–I) but 
was not associated with any increases in plasma concentrations of  urea or creatinine (Supplemental 
Figure 4). Thus, these studies demonstrated that cinacalcet is effective in vivo and can reduce raised 
plasma calcium and PTH concentrations observed in Gna11 mutant mice with a loss-of-function Gα11 
mutation, which is representative of  FHH2.
Discussion
We have established a mouse model for FHH2, and this will enable the calcitropic roles of  Gα11 to be 
further evaluated and also facilitate further pathophysiological studies that are difficult to pursue in the 
few reported patients with this condition. Our results revealed that heterozygous-affected (Gna11+/195G) 
mice had a similar plasma biochemical phenotype to that reported for FHH2 patients, who also harbor 
heterozygous loss-of-function Gα11 mutations (Table 5) (3, 10). Thus, Gna11
+/195G mice had mild hypercal-
cemia in association with normal plasma PTH concentrations; they also had no alterations in the plasma 
concentrations of  phosphate and creatinine, or in alkaline phosphatase activity, which is consistent with 
Figure 4. Calcitropic phenotype of 
Gna11+/+, Gna11+/195G, and Gna11195G/195G 
mice. (A) Plasma albumin–adjusted 
calcium concentrations, (B) plasma 
phosphate concentrations, (C) plasma 
parathyroid hormone (PTH) concen-
trations, and (D) fractional excretion 
of calcium (FECa) of Gna11+/+ (circles), 
Gna11+/195G (squares), and Gna11195G/195G 
(triangles) mice, respectively. Com-
bined data from males and females 
are shown. Mean ± SEM values for 
the respective groups are indicated by 
the solid bars. A Kruskal-Wallis test 
followed by Dunn’s test for nonpara-
metric pairwise multiple comparisons 
were used for analysis of A–D. *P < 
0.05, **P < 0.01, ***P < 0.001.
Table 3. Urine biochemical profile of Gna11+/+, Gna11+/195G, and Gna11195G/195G mice
Parameter Male Female
Gna11+/+ Gna11+/195G Gna11195G/195G Gna11+/+ Gna11+/195G Gna11195G/195G
24hr Ca 4.9 ± 0.4 (n = 9) 5.9 ± 0.5 (n = 13) 6.4 ± 0.7 (n = 13) 11.7 ± 1.3 (n = 10) 16.3 ± 2.4 (n = 15) 17.0 ± 1.7 (n = 12)
Ca/Cr 0.30 ± 0.02 (n = 9) 0.31 ± 0.02 (n = 12) 0.32 ± 0.02 (n = 13) 0.57 ± 0.06 (n = 10) 0.75 ± 0.10 (n = 15) 0.88 ± 0.13 (n = 12)
FECa 1.9 ± 0.3 (n = 11) 1.5 ± 0.2 (n = 13) 1.4 ± 0.2 (n = 12) 2.9 ± 0.3 (n = 10)B 3.1 ± 0.3 (n = 13)C 3.0 ± 0.2 (n = 9)C
FENa  5.3 ± 0.4 (n = 12) 4.7 ± 0.4 (n = 13) 5.2 ± 0.5 (n = 13) 6.1 ± 0.2 (n = 10) 6.1 ± 0.3 (n = 15) 6.0 ± 0.3 (n = 13)
FEK 0.20 ± 0.004 (n = 11) 0.18 ± 0.02 (n = 13) 0.20 ± 0.01 (n = 13) 0.21 ± 0.01 (n = 10) 0.23 ± 0.01 (n = 15) 0.21 ± 0.01 (n = 13)
TmP/GFR 1.6 ± 0.1 (n = 9) 1.6 ± 0.1 (n = 12) 1.5 ± 0.1 (n = 12) 2.0 ± 0.1 (n = 10) 1.7 ± 0.1 (n = 15)A 1.6 ± 0.1 (n = 13)A
Parameters were measured using urine samples obtained over a 24-hour period. Urinary calcium excretion values are shown as μmol/24 hours. Calcium/
creatinine ratios (Ca/Cr) are shown as mmol/mmol. Fractional excretion (FE) of Ca and Na are multiplied by 1,000. TmP/GFR, ratio of tubular maximum 
reabsorption of phosphate (TmP) to GFR. All values are expressed as mean  ±  SEM. A Kruskal-Wallis test followed by Dunn’s test for nonparametric pairwise 
multiple comparisons were used for all analyses. AP < 0.05 compared with respective Gna11+/+ mice. BP < 0.05, CP < 0.001 compared with respective male mice.
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the reported phenotype of  FHH2 patients (Table 5) (3, 10). Gna11+/195G mice additionally had normal 
plasma magnesium concentrations, which is consistent with one reported FHH2 proband (3) but which 
contrasts with the hypermagnesemia reported in a multigenerational FHH2 kindred (3). A key finding of  
this study is that Gna11+/195G and Gna11195G/195G mice had no alterations in urinary calcium excretion, and 
this would be consistent with studies of  FHH2 patients, which have reported that not all FHH2 patients 
have a low fractional excretion of  calcium (Table 5) (3, 10). The absence of  a urinary calcium phenotype 
in Gna11+/195G and Gna11195G/195G mice is also consistent with the reported findings in mice and humans 
harboring germline gain-of-function Gα11 mutations that is associated with hypocalcemia and reduced 
plasma PTH concentrations but with mild or no alterations in urinary calcium excretion (25–27). These 
studies highlight a potential difference in the calcitropic phenotype of  disorders caused by germline Gα11 
mutations and that of  disorders caused by germline CaSR mutations, and they suggest that the Gα11 pro-
tein may not play a major role in the renal handling of  calcium. Thus, it remains to be established wheth-
er hypocalciuria represents a major component of  the FHH2 disorder in humans. Furthermore, DXA 
analysis did not reveal any alterations in the BMD values of  Gna11195G/195G mice, which also suggests that 
the Gα11 protein may not influence bone mass.
Our studies of  homozygous-affected (Gna11195G/195G) mice have highlighted the importance of  Gα11 
for parathyroid gland function and PTH secretion, as Gna11195G/195G mice had more pronounced hyper-
calcemia and hypophosphatemia, and significantly raised plasma PTH concentrations, consistent with 
primary hyperparathyroidism (28). Moreover, female Gna11195G/195G mice also had significant elevations 
of  plasma alkaline phosphatase activity, which is consistent with an elevated bone turnover associated 
with this likely primary hyperparathyroidism. However, the hypercalcemic phenotype of  Gna11195G/195G 
mice was, in general, milder than that observed in humans or mice harboring biallelic loss-of-function 
CaSR mutations, which typically lead to the life-threatening disorder of  NSHPT (12, 24). A possible 
explanation for the milder hypercalcemic phenotype observed in the Gna11195G/195G mice is that the loss 
of  Gα11 function caused by the Asp195Gly mutation in vivo was partially compensated by the WT Gαq 
protein, which in the parathyroid glands continues to mediate signal transduction by the CaSR. Indeed, 
the importance of  the Gα11 and Gαq proteins for parathyroid gland function has been demonstrated by 
studies of  mice with a parathyroid-specific ablation of  both Gα11 and Gαq, which have been reported to 
develop features of  NSHPT such as severe hypercalcemia, skeletal demineralization, growth retarda-
tion, and early postnatal death (7). The hypercalcemia observed in Gna11195G/195G mice was more severe 
in females compared with males, and such sex differences have not previously been reported in studies 
of  FHH patients. However, sex differences have been noted in primary hyperparathyroidism patients, 
with females being more commonly affected than males (29). Moreover, estrogen may play a role in the 
pathogenesis and severity of  primary hyperparathyroidism, as highlighted by a study that showed the 
potential involvement of  estrogen signaling in parathyroid function and disease (30); such effects may 
have contributed to the more severe hypercalcemia of  female Gna11195G/195G mice.
There is currently no effective treatment for FHH2, and we therefore evaluated the therapeutic 
potential of  cinacalcet, which is a licensed CaSR-positive allosteric modulator (13), for this condition. 
Table 4. Whole body DXA analysis of Gna11+/+, Gna11+/195G, and Gna11195G/195G mice
Parameter Male Female
Gna11+/+ Gna11+/195G Gna11195G/195G Gna11+/+ Gna11+/195G Gna11195G/195G
BMC (g) 0.60 ± 0.01 
(n = 12)
0.62 ± 0.01 
(n = 13)
0.63 ± 0.01 
(n = 14)
0.57 ± 0.01 
(n = 9)
0.59 ± 0.01 
(n = 14)
0.57 ± 0.01 
(n = 12)
BMC (corr) 0.02 ± 0.0004 
(n = 12)
0.02 ± 0.001 
(n = 13)
0.02 ± 0.001 
(n = 14)
0.02 ± 0.001 
(n = 9)
0.02 ± 0.001 
(n = 15)
0.019 ± 0.001 
(n = 12)
BMD (g/cm2) 0.065 ± 0.001 
(n = 12)
0.065 ± 0.001 
(n = 13)
0.069 ± 0.002 
(n = 14)
0.067 ± 0.001 
(n = 9)
0.066 ± 0.001 
(n = 15)
0.067 ± 0.003 
(n = 12)
Fat mass (%) 23.6 ± 0.8 
(12)
21.3 ± 1.1 
(13)
22.0 ± 1.4 
(14)
23.8 ± 1.9 
(n = 9)
27.4 ± 1.5 
(n = 15)
29.0 ± 0.7A 
(n = 12)
DXA, dual-energy X-ray absorptiometry; BMC, bone mineral content; BMC (corr), BMC corrected for body weight; BMD, bone mineral density. All values are 
expressed as mean  ±  SEM. A Kruskal-Wallis test followed by Dunn’s test for nonparametric pairwise multiple comparisons were used for all analyses.  
AP = 0.06 compared with respective Gna11+/+ mice.
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In vitro studies have previously reported that nanomolar concentrations of  cinacalcet can successfully 
rectify the altered signaling responses of  HEK-CaSR cells expressing FHH2-associated Gα11 mutant 
proteins (23). Consistent with these findings, our study showed a 10 nM concentration of  cinacalcet to 
normalize the Ca2+i responses of  HEK-CaSR cells expressing the mutant Gly195 Gα11 protein. More-
over, oral administration of  a single 30 mg/kg cinacalcet dose led to a transient suppression of  PTH 
secretion in Gna11+/195G and Gna11195G/195G mice, and this was associated with a sustained reduction in 
plasma calcium concentrations, which lasted for ≥ 6 hours. This dose of  cinacalcet was well tolerated 
in the mice and did not lead to hypocalcemia, with mean plasma calcium concentrations remaining 
at > 2.0 mmol/l. However, transient hyperphosphatemia was noted in cinacalcet-treated mice, which 
was likely to be a consequence of  suppressed PTH secretion (31). These results suggest that calcimi-
metics such as cinacalcet will likely be of  benefit for FHH2 patients, who also harbor loss-of-function 
Gα11 mutations (23).
In summary, we have established a mouse model for FHH2 and have shown the in vivo efficacy of  
cinacalcet in reducing plasma calcium and PTH concentrations, thereby illustrating the potential utility of  
this CaSR allosteric modulator for the treatment of  hypercalcemia in patients with FHH2.
Figure 5. In vivo effect of cinacalcet on plasma PTH, calcium, and phosphate concentrations of Gna11+/+, Gna11+/195G, and Gna11195G/195G mice. (A–C) 
Plasma parathyroid hormone (PTH), (D–F) plasma albumin–adjusted calcium, and (G–I) plasma phosphate concentrations are shown at 0, 1, 2, 4, 6, and 
24 hours following oral gavage administration of a single 30 mg/kg cinacalcet dose. Mean values for the respective groups are indicated by solid bars. 
n = 4–5 mice per study time point. Squares, males; circles, females. A Kruskal-Wallis test followed by Dunn’s test for nonparametric pairwise multiple 
comparisons were used for analysis of A–I. *P < 0.05, **P < 0.01 compared with respective untreated mice. $Untreated Gna11195G/195G mice were signifi-
cantly (P < 0.05) hypercalcemic compared with untreated Gna11+/+ mice.
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Methods
Animals. ENU-treated G0 C57BL/6J male mice (The Jackson Laboratory) were mated to C3H/HeH 
(C3H) mice (MRC Harwell) to produce G1 progeny, and tissue-DNA samples from > 10,000 G1 ENU 
mutagenized male mice — together with their sperm — was archived, as reported (14). These tissue-DNA 
samples were used to identify Gna11 variants by melt curve analysis of  PCR products utilizing a Lights-
canner and gene-specific primers (BioFire Diagnostics Inc.), and sperm from mice with Gna11 variants was 
used for IVF to generate G2 progeny on a C3H background strain, as reported (16, 24). Heterozygous-af-
fected (Gna11+/195G) mutant male and female mice were intercrossed to generate homozygous (Gna11195G/195G) 
mice, which were studied along with their Gna11+/195G and WT (Gna11+/+) littermates. All study mice were 
housed in a controlled environment at the MRC Harwell Institute in accordance with UK Home Office and 
MRC Welfare guidance. Mice were fed on a standard diet (Rat and Mouse number 3, Special Diet Services) 
that contained 1.15% calcium, 0.58% phosphate, and 4089 IU/kg of  vitamin D, and they were provided 
with water ad libitum (25, 32).
Compounds. Cinacalcet (AMG-073 HCL) was obtained from Cambridge Bioscience (catalog 
CAY16042) and dissolved in a 20% aqueous solution of  2-hydroxypropyl-β-cyclodextrin (MilliporeSigma, 
catalog H107) prior to use in in vitro and in vivo studies.
DNA sequence analysis. Genomic DNA was isolated from auricular biopsies using DNA extraction buffer 
(10 mM NaCl, 20 mM Tris-HCl, pH 8.0, 1 mM EDTA, 10% SDS; MilliporeSigma) and Proteinase K solution 
(Thermo Fisher Scientific) (25). Genomic DNA was used with Gna11 gene–specific primers (MilliporeSigma) 
to perform PCR amplification, followed by dideoxynucleotide sequencing using the BigDye Terminator v3.1 
Cycle Sequencing Kit and an automated detection system (ABI 3730 Automated capillary sequencer, Ther-
mo Fisher Scientific), as reported (25). MutationTasting (http://www.mutationtaster.org/) and Polyphen-2 
software was used to predict variant pathogenicity (33, 34). The Gna11 germline mutation was confirmed by 
HaeIII restriction endonuclease analysis (New England Biolabs), as previously described (3, 4).
Protein sequence alignment and 3-D modeling. Protein sequences of  Gα11 orthologs and paralogs were 
aligned with Clustal Omega (35). The PyMOL Molecular Graphics System (Version 1.2r3pre, Schrödinger 
LLC) was used for structural modeling based on the complexed crystal structure of  Gαq, which has 90% 
Table 5. Comparison of the phenotypes of FHH2 patients with mice harboring a loss-of-function Gna11 mutation
Parameter FHH2 patients FHH2 mouse model
Proband 1 Proband 2 Proband 3 Gna11+/195G Gna11195G/195G
Gα11 mutation Leu135Gln 
(Het)
Ile200del 
(Het)
Thr54Met 
(Het)
Asp195Gly 
(Het)
Asp195Gly 
(Hom)
Serum/plasma biochemistry
Calcium H H H H H
Magnesium N H nr N N
Phosphate N N N N L
Creatinine N N N N N
ALP N N nr N HA
PTH N N N N H
TSHB N nr nr  nr nr
Urine biochemistry
FECa LC N N N N
InfertilityB nr No nr No nr
Reference Nesbit et al. 
2013 (3)
Nesbit et al. 
2013 (3)
Gorvin et al. 
2016 (10)
- -
AAlkaline phosphatase (ALP) is increased in homozygous females; BThyrotropin (TSH) reported as 4.05 mU/l (normal 0.35–5.5) (3). Thyrotropin-releasing 
hormone receptor (TRHR) and gonadotropin-releasing hormone receptor (GnRHR), which are both GPCRs signal via Gαq/11 proteins (40). However, FHH2 
patients with Gα11 loss-of-function mutations have not been reported to have hypothyroidism, high-circulating TSH concentrations (3), or infertility (3, 41), 
indicating that they are unlikely to have thyroid hormone or gonadotropin hormone deficiencies. The findings of normal body weights in mutant Gna11+/195G 
and Gna11195G/195G mice (Table 2) and fertility in mutant Gna11+/195G mice (Table 1) suggest that these Gna11 mutant mice, similar to the FHH2 patients, are 
also unlikely to have deficiencies of thyroid hormone or gonadotropin hormone. CFractional excretion of calcium (FECa) is < 0.01, consistent with the 
phenotype of FHH. Het, heterozygous; Hom; homozygous; N, normal; PTH, parathyroid hormone; H, high; L, low; nr, not reported.
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identity with Gα11 at the amino acid level (Protein Data Bank, accession no. 4GNK; https://www.rcsb.org/
pdb/home/home.do) (18). The effect of  the Gα11 mutations upon Gα11 structure was modeled using the 
PyMod plug-in and Modeller (36).
Cell culture and transfection. Functional studies were undertaken using a human GNA11 construct (3), 
as the human and mouse Gα11 proteins share an overall amino acid identity of  98% (25) and are 100% 
identical in the region surrounding the mutated site. The Gly195 mutation was introduced by site-direct-
ed mutagenesis (QuikChange Lightning, Agilent Technologies) into a pBI-CMV2-GNA11-GFP expres-
sion construct, as reported (3), and WT and mutant pBI-CMV2-GNA11-GFP constructs were transiently 
transfected into HEK293 cells stably expressing the full-length human CASR cDNA (HEK-CaSR), as 
described (3). HEK-CaSR cells were maintained in DMEM-Glutamax media (Thermo Fisher Scien-
tific) with 10% FBS (Gibco) and 400 μg/ml geneticin (Thermo Fisher Scientific) at 37°C, 5% CO2 (3). 
Successful transfection was confirmed by visualizing GFP fluorescence using an Eclipse E400 fluores-
cence microscope with an epifluorescence filter, and images were captured using a DXM1200C digital 
camera and NIS Elements software (Nikon) (3, 11). The expression of  Gα11, CaSR, GFP, calnexin, and 
GAPDH proteins was confirmed by Western blot analyses using anti-Gα11 (D-6, sc-390382, Santa Cruz 
Biotechnologies Inc.), anti-CaSR (5C10, ADD; ab19347; Abcam), anti-GFP (B-2, sc-9996, Santa Cruz 
Biotechnologies Inc.), anti-calnexin (AB2301, Millipore), and anti-GAPDH (AM4300, Ambion) anti-
bodies, respectively. The Western blots were visualized using an Immuno-Star Western C kit (Bio-Rad) 
on a Bio-Rad Chemidoc XRS+ system (3, 10).
Measurement of  Ca2+i responses. The Ca
2+
i responses of  HEK-CaSR cells expressing WT or mutant Gα11 
proteins were measured by Fluo-4 calcium assays adapted from methods previously published (22). HEK-
CaSR cells were plated in poly-L-lysine–treated black-walled 96-well plates (Corning) and were transient-
ly transfected with 1,000 μg/ml pBI-CMV2-GNA11-GFP. On the following day, cells were incubated in 
serum-free media for 2 hours and then loaded with the Fluo-4 Ca2+–binding dye, prepared according to 
manufacturer’s instructions (Invitrogen). Cells were loaded for 40 minutes at 37°C. Then, either a 20% 
aqueous solution of  2-hydoxypropyl-β-cyclodextrin (vehicle) or 10 nM cinacalcet was added, and cells were 
incubated for a further 20 minutes at 37°C (19). Baseline measurements were made, and increasing doses 
of  CaCl2 were injected into each well, using the PHERAstar microplate reader (BMG Labtech) automated 
system. Changes in Ca2+i were recorded on a PHERAstar instrument (BMG Labtech) at 37°C with an exci-
tation filter of  485 nm and an emission filter of  520 nm. The peak mean fluorescence ratio of  the transient 
response after each individual stimulus was measured using MARS data analysis software (BMG Labtech) 
and expressed as a normalized response. Nonlinear regression of  concentration-response curves was per-
formed with GraphPad Prism using the normalized response at each [Ca2+]o for each separate experiment 
for the determination of  the EC50 values.
Metabolic cage studies and biochemical analysis. Thirteen- to 15-week-old mice were individually housed in 
metabolic cages (Techniplast) for 24 hours with free access to food and water. Mice were allowed to accli-
matize to their environment over a 72-hour period, as described (37), prior to collection of  24-hour urine 
samples. Twenty-four–hour urine samples were collected in tubes containing sodium azide, and blood sam-
ples were collected from the lateral tail vein under topical local anesthesia (38) or from the retro-orbital vein 
into lithium heparin Microvette tubes (Sarstedt) following terminal isoflurane anesthesia, as described (25, 
32). Plasma and urine were analyzed for sodium, potassium, total calcium, phosphate, magnesium, urea, 
creatinine, and alkaline phosphatase activity on a Beckman Coulter AU680 analyzer (25, 32). Plasma cal-
cium was adjusted for variations in albumin concentrations using the formula: plasma calcium (mmol/l) – 
([plasma albumin – mean albumin (g/l) of  respective male and female WT mice] × 0.02), as reported (39). 
Hormones were measured as follows: PTH using a 2-site ELISA specific for mouse intact PTH (Immutop-
ics); 1,25-dihydroxyvitamin D by a 2-step process involving purification by immunoextraction and quan-
tification by enzyme immunoassay (Immunodiagnostic Systems); and FGF-23 using a 2-site ELISA kit 
(Kainos Laboratories), as described (25, 39). The fractional excretion of  sodium, potassium, and calcium 
were calculated using the formula Ux/Px × PCr/UCr, where Ux is the urinary concentration of  the filtered 
substance (substance x) in mmol/l, Px is the plasma concentration of  substance x in mmol/l, UCr is the uri-
nary concentration of  creatinine in mmol/l, and PCr is the plasma concentration of  creatinine in mmol/l. 
The ratio of  tubular maximum reabsorption of  phosphate to GFR (TmP/GFR) was calculated using the 
following formula: PPi × (1 – [UPi/PPi × PCr/UCr ]), where PPi is the plasma concentration of  phosphate and 
UPi is the urine concentration of  phosphate (25, 32).
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Skeletal imaging. Bone mineral content and density were assessed by whole body DXA scanning, which 
was performed on mice anesthetized by inhaled isoflurane and using a Lunar Piximus densitometer (GE 
Medical Systems), as reported (25). DXA images were analyzed using Piximus software, as reported (25).
Statistics. All in vitro studies involved 8 biological replicates. Statistical comparisons of  the Ca2+i EC50 
responses were undertaken using the F-test, as reported (3). For the in vivo studies, a Kruskal-Wallis test 
was undertaken for multiple comparisons, and any significant differences identified were further assessed 
using the Dunn’s test for nonparametric pairwise multiple comparisons (25). All analyses were performed 
using GraphPad Prism (GraphPad), and a value of  P < 0.05 was considered significant for all analyses.
Study approval. Animal studies were approved by the MRC Harwell Institute Ethical Review Commit-
tee and were licensed under the Animal (Scientific Procedures) Act 1986, issued by the UK Government 
Home Office Department (PPL30/2433 and PPL30/3271).
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